Artelo Biosciences, Inc. (ARTL): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo dinâmico da biotecnologia, a Artelo Biosciences, Inc. (ARTL) surge como uma força pioneira, aproveitando o potencial transformador da terapêutica baseada em canabinóides para atender às necessidades médicas críticas não atendidas. Ao navegar estrategicamente no cenário complexo da inovação farmacêutica, esta empresa de ponta está pronta para revolucionar abordagens de tratamento para dor e distúrbios metabólicos por meio de seu sofisticado ecossistema de pesquisa e desenvolvimento. Mergulhe na intrincada tela do modelo de negócios que revela como o Artelo está construindo metodicamente um caminho para soluções médicas inovadoras que podem potencialmente remodelar o atendimento ao paciente e o entendimento científico.

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para colaboração de desenvolvimento de medicamentos

Instituição	Foco de colaboração	Área de pesquisa
Universidade da Califórnia San Diego	Pesquisa pré -clínica	Terapêutica do câncer
Universidade Estadual de San Diego	Estudos de Biologia Molecular	Pesquisa do mecanismo de drogas

Organizações de pesquisa de contratos farmacêuticos (CROs)

Nome do CRO	Serviços prestados	Valor do contrato
Icon plc	Gerenciamento de ensaios clínicos	$750,000
Medpace, Inc.	Suporte de conformidade regulatória	$500,000

Potenciais investidores estratégicos e parceiros de biotecnologia

• Perceptive Advisors LLC
• Fundo de Investimento em Saúde Sabby
• Capital do Armistício

Centros de pesquisa médica para ensaios clínicos

Centro de Pesquisa	Fase de ensaios clínicos	Área terapêutica
MD Anderson Cancer Center	Fase II	Oncologia
Memorial Sloan Kettering Cancer Center	Fase I/II	Terapêutica do câncer

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento terapêuticos baseados em canabinóides

A partir do quarto trimestre 2023, a Artelo Biosciences se concentrou no desenvolvimento de soluções terapêuticas baseadas em canabinóides, com uma ênfase específica em:

• ART26 Programa direcionado a cuidados de apoio ao câncer
• Tecnologias de plataforma de receptores canabinóides
• Precision Medicine abordes em oncologia

Área de foco de pesquisa	Estágio atual	Investimento
ART26 CUIDADO DE APOIO	Desenvolvimento pré -clínico	US $ 1,2 milhão
Plataforma do receptor canabinóide	Pesquisa exploratória	$750,000

Desenvolvimento de medicamentos pré -clínicos e clínicos

As despesas de pesquisa e desenvolvimento para 2023 totalizaram US $ 3,4 milhões, com foco primário em:

• Triagem molecular
• Testes farmacológicos
• Preparação de novos medicamentos para investigação (IND)

Candidato a drogas	Fase de desenvolvimento	Linha do tempo estimada
ART26	Pré -clínico	2024-2025

Gerenciamento de propriedade intelectual e arquivamento de patentes

Estratégia de Propriedade Intelectual a partir de 2024:

• Aplicações de patentes ativas totais: 7
• Orçamento de acusação de patente: US $ 450.000
• Cobertura geográfica: Estados Unidos, Europa e Ásia

Conformidade regulatória e gerenciamento de ensaios clínicos

Métricas de conformidade regulatória para 2023-2024:

Área de conformidade	Status	Investimento
Interação FDA	Comunicação ativa	$275,000
Preparação de ensaios clínicos	Em andamento	US $ 1,1 milhão

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: Recursos -chave

Portfólio farmacêutico de canabinóides proprietários

A Artelo Biosciences mantém um portfólio focado de candidatos farmacêuticos baseados em canabinóides:

• ART26 (indicação de anorexia)
• ART27 (Cuidado de suporte ao câncer)
• ART30 (Condições inflamatórias)

Equipe de Pesquisa e Desenvolvimento Científica

Composição da equipe	Número
Pessoal total de P&D	12 funcionários
Ph.D. Pesquisadores	7 pesquisadores
Bolsistas de pós -doutorado	3 bolsistas

Instalações de laboratório e pesquisa especializadas

Localização: San Diego, Califórnia

• Espaço total da instalação de pesquisa: 5.000 pés quadrados.
• Equipamento avançado de pesquisa canabinóide
• Capacidades de laboratório de nível 2 de biossegurança

Propriedade intelectual e portfólio de patentes

Categoria de patentes	Número de patentes
Patentes emitidas	6 patentes
Aplicações de patentes pendentes	4 APLICAÇÕES
Jurisdições de patentes	Estados Unidos, Europa

Capital financeiro para pesquisa em andamento

Métrica financeira	Quantia
Caixa e equivalentes em dinheiro (Q4 2023)	US $ 7,2 milhões
Despesas de pesquisa e desenvolvimento (2023)	US $ 5,4 milhões
Despesas operacionais totais (2023)	US $ 9,1 milhões

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: Proposições de valor

Soluções terapêuticas inovadoras visando necessidades médicas não atendidas

O Artelo Biosciences se concentra no desenvolvimento de novos tratamentos farmacêuticos com posicionamento de mercado específico:

Oleoduto de produto	Indicação alvo	Estágio de desenvolvimento	Tamanho potencial de mercado
ART26	Cuidados de apoio ao câncer	Pré -clínico	US $ 3,2 bilhões
ART27	Distúrbios metabólicos	Investigação	US $ 2,7 bilhões

Desenvolvimento de tratamentos farmacêuticos baseados em canabinóides

As principais áreas de foco de pesquisa incluem:

• Desenvolvimento de drogas canabinóides proprietárias
• Direcionando vias moleculares específicas
• Formulações de canabinóides de grau farmacêutico

Potenciais tratamentos inovadores

Área de tratamento	Alvo terapêutico	Mecanismo único
Gerenciamento da dor	Sistema endocanabinóide	Modulação seletiva do receptor
Distúrbios metabólicos	Metabolismo lipídico	Intervenção da via molecular

Abordagem científica avançada para o desenvolvimento de medicamentos canabinóides

Investimento de pesquisa: US $ 2,1 milhões em 2023

• Plataforma proprietária de descoberta de medicamentos
• Parcerias de pesquisa colaborativa
• Técnicas avançadas de triagem molecular

Despesas totais de P&D: US $ 4,3 milhões no ano fiscal de 2023

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: Relacionamentos ao cliente

Engajamento direto com profissionais médicos

A partir do quarto trimestre 2023, o Artelo Biosciences mantém estratégias de divulgação direcionadas com as seguintes métricas:

Categoria de engajamento	Número de interações
Especialistas em oncologia contatados	237
Profissionais de pesquisa em neurologia	156
Investigadores de ensaios clínicos	89

Conferência Científica e Participação de Eventos da Indústria

A Artelo Biosciences participou dos seguintes eventos importantes em 2023:

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• ENCERIÇÃO DE NEUROSCIÊNCIA 2023
• Organização de Inovação de Biotecnologia (BIO) Convenção Internacional

Comunicação transparente do progresso da pesquisa

Métricas de comunicação de pesquisa para 2023:

Canal de comunicação	Freqüência
Comunicados de imprensa	7
Apresentações de investidores	4
Submissões de publicação científica	3

Possíveis negociações de licenciamento e parceria

Estatísticas de engajamento de parceria para 2023:

• Discussões de parceria farmacêutica: 5 negociações ativas
• Propostas de colaboração de pesquisa: 3 em revisão
• Possíveis oportunidades de licenciamento: 2 discussões em estágio avançado

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: canais

Publicações científicas e revistas revisadas por pares

A Artelo Biosciences utiliza os seguintes canais de comunicação científica:

Tipo de publicação	Número de publicações (2023)	Faixa de fatores de impacto
Revistas oncológicas	3	2.5 - 4.2
Revistas de farmacologia	2	3.1 - 3.7

Conferências médicas e simpósios de biotecnologia

Detalhes da participação na conferência:

Tipo de conferência	Número de apresentações	Retenção dos participantes
Conferências de oncologia	4	1,200 - 1,500
Simpósios de biotecnologia	2	800 - 1,000

Comunicação direta com parceiros farmacêuticos

• Parcerias farmacêuticas ativas: 3
• Frequência de comunicação de parceria: reuniões trimestrais
• Acordos de pesquisa colaborativa: 2

Plataformas de relações com investidores e comunicações financeiras

Canal de comunicação	Freqüência	Alcance do investidor
Chamadas de ganhos trimestrais	4 vezes por ano	150 - 200 investidores institucionais
Conferências de investidores	2-3 por ano	100 - 150 investidores em potencial
Reunião Anual dos Acionistas	1 tempo por ano	75 - 100 acionistas

Plataformas totais de comunicação de investidores: 5 canais distintos

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: segmentos de clientes

Empresas farmacêuticas

A partir de 2024, a Artelo Biosciences tem como alvo empresas farmacêuticas com possíveis oportunidades de pesquisa e desenvolvimento colaborativo.

Segmento farmacêutico	Nível de engajamento potencial	Áreas de foco
Farmacêutico focado em oncologia	Alto	Pesquisa de terapêutica do câncer
Empresas farmacêuticas de neurociência	Médio	Tratamentos de transtorno neurológico

Instituições de Pesquisa Médica

O Artelo Biosciences colabora com instituições acadêmicas e de pesquisa.

• Institutos Nacionais de Saúde (NIH) Programas de pesquisa financiados
• Centros de Pesquisa Médica Baseada na Universidade
• Laboratórios especializados de pesquisa de biotecnologia

Profissionais de saúde

Profissionais de saúde -alvo especializados em áreas terapêuticas específicas.

Especialidade	Interesse potencial	Tamanho do mercado -alvo
Oncologistas	Alto	Aproximadamente 15.000 nos Estados Unidos
Neurologistas	Médio	Aproximadamente 12.000 nos Estados Unidos

Pacientes com necessidades terapêuticas específicas

Focado nas populações de pacientes com necessidades médicas não atendidas.

• Pacientes com câncer com opções de tratamento limitadas
• Pacientes com transtorno neurológico
• Pacientes que necessitam de abordagens terapêuticas inovadoras

Segmento de pacientes	População estimada	Tamanho potencial de mercado
Pacientes com câncer avançado	Aproximadamente 1,9 milhão de novos casos anualmente	US $ 150 bilhões em potencial mercado
Pacientes com transtorno neurológico	Mais de 100 milhões globalmente	Mercado potencial de US $ 100 bilhões

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o exercício fiscal encerrado em 31 de dezembro de 2022, a Artelo Biosciences registrou despesas de P&D de US $ 4.261.000.

Ano fiscal	Despesas de P&D ($)
2022	4,261,000
2021	3,987,000

Custos de ensaios clínicos

As despesas de ensaios clínicos para biosciências do Artelo em 2022 foram de aproximadamente US $ 2.845.000.

• Foco primário no desenvolvimento clínico ART26
• Estudos em andamento em cuidados de apoio ao câncer

Manutenção da propriedade intelectual

A propriedade intelectual anual e as despesas relacionadas a patentes foram de US $ 387.000 em 2022.

Overhead administrativo e operacional

Categoria de despesa	Valor ($)
Despesas gerais e administrativas	2,673,000
Salários e custos de pessoal	1,942,000

Despesas de conformidade regulatória

A conformidade regulatória e os custos de consultoria relacionados foram de aproximadamente US $ 512.000 em 2022.

Despesas operacionais totais para 2022: US $ 11.618.000

Artelo Biosciences, Inc. (ARTL) - Modelo de negócios: fluxos de receita

Potencial licenciamento futuro de produtos

A partir do quarto trimestre 2023, a Artelo Biosciences não possui receita ativa de licenciamento de produtos. As possíveis oportunidades de licenciamento permanecem sob exploração para seu pipeline de desenvolvimento farmacêutico.

Bolsas de pesquisa

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	$350,000	2023
Pesquisa de Inovação em Pequenas Empresas (SBIR)	$250,000	2023

Acordos de parceria estratégica

Status da parceria estratégica atual: Colaborações externas limitadas a partir de 2024.

Vendas potenciais de produtos farmacêuticos

• ART26 Pipeline direcionando a terapêutica do câncer
• Desenvolvimento de estágio pré -clínico
• Sem vendas de produtos comerciais atuais

Pagamentos marcantes da pesquisa colaborativa

Pesquisa Milestone	Pagamento potencial	Status
Conclusão do desenvolvimento pré -clínico	$500,000	Pendente
Iniciação de ensaios clínicos de fase I	$750,000	Não alcançado

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Value Propositions

You're looking at the core value Artelo Biosciences, Inc. (ARTL) brings to the table right now, late in 2025. It's all about novel mechanisms targeting areas where current options just aren't cutting it.

Novel, non-opioid, non-steroidal analgesic for chronic pain (ART26.12)

ART26.12 is positioned as the first orally active Fatty Acid Binding Protein 5 (FABP5) inhibitor evaluated in humans. This novel approach targets the multibillion-dollar pain management market, which exceeded $97 billion globally in 2023 and is projected to hit $159 billion by 2030. The initial Phase 1 Single Ascending Dose (SAD) study involved 49 healthy volunteers, successfully testing single doses up to 1050 milligrams. The next step, a Multiple Ascending Dose (MAD) study protocol, is being finalized, with plans to start in Q4 2025. Initial clinical development is aimed at chemotherapy-induced peripheral neuropathy (CIPN), for which there is currently no FDA-approved treatment.

Here's a quick look at the clinical progression for ART26.12:

Metric	Value/Status (Late 2025)
Mechanism	First selective FABP5 inhibitor in humans
Phase 1 SAD Enrollment	49 subjects
Max Single Dose Tested	1050 milligrams
Next Planned Study	Multiple Ascending Dose (MAD) starting Q4 2025
Initial Indication Target	Chemotherapy-induced peripheral neuropathy (CIPN)

First-in-class treatment potential for cancer anorexia-cachexia syndrome (ART27.13)

ART27.13, a peripherally acting cannabinoid receptor agonist, addresses cancer anorexia-cachexia syndrome (CACS), a condition affecting up to 80% of cancer patients and lacking any FDA-approved therapy. The drug has been in seven clinical studies involving over 280 participants. Artelo Biosciences is expecting initial data from the Phase 2 CAReS trial in Q3 2025. Interim Phase 2 results showed compelling efficacy: patients on the top dose achieved an average +6.4% weight gain compared to placebo participants losing an additional 5%. Furthermore, these patients showed a +4.2% increase in lean body mass. The company believes this data positions them well to secure a development partner, avoiding the need to internally fund a Phase 3 trial.

Improved pharmacokinetics and efficacy via proprietary CBD cocrystal (ART12.11)

ART12.11 is Artelo Biosciences' proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal. Preclinical studies demonstrated that ART12.11 significantly outperformed standard cannabidiol (CBD) alone in reducing stress-induced depression and anxiety symptoms. A key value driver is its improved oral bioavailability, leading to higher plasma concentrations of CBD and its metabolite compared to conventional CBD formulations. Tablet prototypes have been evaluated, each containing 100mg of CBD, with the potential to increase drug loading. The US composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has been granted or validated in 19 additional countries. For context, the FDA-approved CBD therapy, Epidiolex®, reported net sales over $845 million in 2023.

The advantages of ART12.11 over standard CBD include:

• Superior oral bioavailability demonstrated in studies.
• Robust antidepressant and anxiolytic-like effects in animals.
• Comparable pharmacokinetics to Epidiolex® in canine studies.
• Potential for a solid dosage form, improving stability and adherence.
• Patent protection extending until December 10, 2038.

Addressing large, underserved markets with high unmet medical need

Artelo Biosciences is focused on three main areas, all characterized by significant unmet needs. The company reported a net loss of $3.1 million for the quarter ended September 30, 2025, reflecting the heavy investment required to advance these novel candidates. Cash and investments stood at $1.7 million as of September 30, 2025, following a September 2025 public offering that brought in gross proceeds of $3.0 million to support these clinical objectives.

The pipeline targets these large markets:

• Chronic Pain: Non-opioid, non-steroidal analgesic potential.
• Cancer Supportive Care: CACS, which currently has no FDA-approved treatment.
• Neurological/Mood: Depression and anxiety, addressing limitations of conventional CBD.

Analyst consensus suggests a significant upside, with the average twelve-month price target at $24.00, representing a forecasted upside of 1,287.28% from the current price of $1.73. Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Customer Relationships

You're looking at how Artelo Biosciences, Inc. (ARTL) manages its connections with the key groups that drive its clinical and financial success. For a clinical-stage pharma company, these relationships are about scientific validation and securing future funding or partnerships.

Direct, high-touch engagement with potential pharmaceutical partners

Artelo Biosciences, Inc. focuses its direct engagement on securing strategic alliances, which is critical given its clinical-stage status. The company reports that the positive interim Phase 2 data for ART27.13 has attracted meaningful partnering interest from several pharmaceutical companies. Also, partnering interest continues to expand for ART26.12, the lead Fatty Acid Binding Protein 5 (FABP5) inhibitor. This suggests direct, high-touch interactions are centered around data readouts and pipeline progress.

Scientific communication via presentations at medical conferences

Scientific communication is a primary method for engaging the medical and research community, which indirectly influences potential partners and KOLs. Artelo Biosciences, Inc. actively presented data throughout 2025 at several key events:

• Presented interim Phase 2 Cancer Appetite Recovery Study (CAReS) data on ART27.13 at the 2025 Cancer Cachexia Society Conference.
• Presented expanded data on ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15-16, 2025, in Boston, Massachusetts.
• Presented data on ART12.11 at the International Medical Cannabis Conference (IMCCB-25) in Bern, Switzerland on February 13-14, 2025.
• Presented new data validating ART26.12 in osteoarthritis at the British Pain Society Conference.

Furthermore, the company reinforced its scientific standing with the publication of a peer-reviewed article on the Role of Fatty Acid Binding Proteins in Cancer on November 4, 2025.

Investor relations and transparent financial reporting

Investor relations centers on providing timely and detailed financial updates to maintain confidence, especially during periods of high research and development (R&D) spending. Artelo Biosciences, Inc. reported its Third Quarter 2025 Financial Results on November 12, 2025. The company also provided a stock snapshot as of November 21, 2025, at 16 PM EST, showing a price of $1.67 and a 52-week range of $1.552 - $28.60. You can see the key financial figures from the Q3 2025 report below:

Financial Metric (Period Ended Sep 30, 2025)	Amount
Net Loss	$3.1 million
Net Loss Per Share (Basic and Diluted)	$3.97
Research and Development Expenses	$1.3 million
General and Administrative Expenses	$1.8 million
Cash and Investments (as of Sep 30, 2025)	$1.7 million

The company actively engaged in capital raising to support operations. During the quarter ended September 30, 2025, Artelo Biosciences, Inc. generated $0.4 million from its At-The-Market Offering Agreement and $3.0 million from a confidentially marketed public offering in September 2025. Separately, the company raised $737,000 from convertible notes.

Relationships with key opinion leaders (KOLs) and clinical researchers

The credibility of the science is often tied directly to the experts involved. Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo Biosciences, Inc., is noted as a presenter of key data, indicating a strong internal scientific leadership that interfaces with the external research community. The company states it is 'led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts.' The interim Phase 2 results for ART27.13, showing an average +6.4% weight gain versus a -5.4% loss on placebo, and a +4.2% lean body mass increase, are the direct output of these clinical researcher relationships.

Here's a quick look at the clinical data points driving these relationships:

• ART27.13 top dose achieved +6.4% average weight gain (vs. placebo -5.4% loss) in CAReS Phase 2.
• ART26.12 Single Ascending Dose (SAD) study involved 49 healthy volunteers.
• ART26.12 SAD study demonstrated single doses up to 1050 milligrams were safe.

Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Channels

You're looking at how Artelo Biosciences, Inc. (ARTL) gets its science and its financing out into the world as of late 2025. It's a mix of traditional pharma outreach and some quite modern capital strategies.

Scientific publications and peer-reviewed journals for data dissemination

Disseminating data through established scientific channels is key for credibility. Artelo Biosciences announced the publication of a peer-reviewed article on the Role of Fatty Acid Binding Proteins in Cancer on November 4, 2025. Also, a comprehensive review detailing the involvement of fatty acid binding proteins in anxiety and mood disorders was published in Neurobiology of Disease. Further, preclinical data supporting ART12.11 in reducing stress-induced depression and anxiety symptoms was announced as published on September 10, 2025.

• Publication in Neurobiology of Disease for FABP inhibitors.
• Peer-reviewed article on FABP in Cancer announced November 4, 2025.
• Preclinical data publication for ART12.11 announced September 10, 2025.

Direct business development outreach to potential pharma acquirers/licensees

The primary channel for monetization right now is attracting partners for late-stage development or acquisition. The interim Phase 2 Cancer Appetite Recovery Study (CAReS) data for ART27.13 has definitely moved the needle here. That data showed the highest dose group achieved an average +6.4% weight gain versus a -5.4% loss in the placebo group, along with a 4.2% increase in lean body mass. This efficacy profile has attracted meaningful partnering interest from several pharmaceutical companies. Also, partnering interest continues to expand for ART26.12, the lead FABP5 inhibitor.

Investor roadshows and digital communications for capital markets

To fund the pipeline, Artelo Biosciences has been very active in capital markets, using both traditional and novel methods. They closed a public offering on October 1, 2025, raising gross proceeds of approximately $2.0 million. This followed a September offering that secured approximately $3.0 million in gross proceeds. The company also executed a significant private placement in August 2025, expecting gross proceeds of about $9.475 million at a price of $10.45 per security. The total cash and investments as of September 30, 2025, stood at $1.7 million. The stock was recently trading around $1.67. Here's a quick look at the capital activity around the Q3 2025 reporting period:

Financing Event/Metric	Amount/Value	Date/Period End
Gross Proceeds from October 1, 2025 Offering	$2.0 million	October 1, 2025
Gross Proceeds from September Offering	$3.0 million	September 2025
Gross Proceeds from August PIPE	Approx. $9.475 million	August 2025
Cash and Investments	$1.7 million	September 30, 2025
Stock Price (Snapshot)	$1.67	Late 2025
Market Capitalization (Reported)	$11.82 million	Late September 2025

They use digital communications, like the November 2025 Investor Presentation, to keep the market informed.

Clinical trial sites for drug development and patient access

The clinical sites are where the rubber meets the road for Artelo Biosciences, Inc. (ARTL). The Phase 1 Single Ascending Dose (SAD) study for ART26.12 was completed in 49 healthy volunteers. The next step, the Multiple Ascending Dose (MAD) study, is being finalized with protocols for a Q4 2025 start. For ART27.13, the Phase 2 CAReS trial is the key channel for generating efficacy data, showing that 6.4% average weight gain in the top dose group. The operational spend reflects this: Research and Development Expenses increased to $1.3 million for the quarter ended September 30, 2025, up from $0.3 million in Q3 2024.

You need to track the progress of these trials closely; here's the data we have on the clinical channel status:

Product Candidate	Trial Status/Milestone	Key Metric/Enrollment
ART26.12	Completed Phase 1 SAD Study	49 healthy volunteers
ART26.12	Finalizing MAD Study Protocol	Target start Q4 2025
ART27.13	Interim Phase 2 CAReS Data Reported	+6.4% average weight gain (highest dose)
ART27.13	Interim Phase 2 CAReS Data Reported	4.2% increase in lean body mass

Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Artelo Biosciences, Inc. (ARTL) as of late 2025. This company is focused on modulating lipid-signaling pathways, which means their customer base is segmented by the specific, high-unmet-need conditions their pipeline candidates are targeting. Honestly, the near-term focus is heavily weighted toward securing a partner for their most advanced asset, ART27.13, given their cash position of $1.7 million as of September 30, 2025.

The customer segments fall into two main groups: the ultimate end-users (patients) and the strategic partners (pharma/biotech companies) who will help bring the therapies to those patients.

For the patients, Artelo Biosciences, Inc. is targeting several distinct, underserved populations:

• Patients with cancer anorexia-cachexia syndrome (CACS).
• Patients suffering from chemotherapy-induced peripheral neuropathy (CIPN).
• Patients with chronic pain, including those with conditions like osteoarthritis.
• Patients with anxiety, mood, and dermatologic disorders, such as psoriasis.

The other critical segment is the corporate one. Artelo Biosciences, Inc. is actively seeking to engage with global pharmaceutical and biotech companies seeking late-stage assets, especially for ART27.13, following positive interim Phase 2 data. This partnering strategy is viewed as the most value-accretive path forward, potentially avoiding the need for Artelo Biosciences, Inc. to internally fund a Phase 3 trial.

Here's a breakdown of the key indications and the associated product candidates, which directly defines the patient customer segments and the market opportunity you should be tracking:

Product Candidate	Target Indication	Key Customer Segment Data Point	Market/Efficacy Metric
ART27.13	Cancer Anorexia-Cachexia Syndrome (CACS)	No FDA-approved treatment currently exists.	Addressable market greater than $3 billion.
ART27.13	CACS	Interim Phase 2 CAReS trial results (Q3 2025).	Average +6.4% weight gain vs. -5.4% loss on placebo.
ART26.12	Chemotherapy-Induced Peripheral Neuropathy (CIPN)	Phase 1 clinical trial initiated (Q4 2024).	Lead Fatty Acid Binding Protein 5 (FABP5) inhibitor.
ART26.12	Chronic Pain (Osteoarthritis)	Preclinical data in a surgical rat model.	Significantly improved weight-bearing function, sustained up to four weeks.
ART26.12	Anxiety, Mood, Dermatologic (Psoriasis)	Preclinical/Review data published.	Antidepressant-like activity on par with sertraline (Zoloft®) in preclinical models.

You should note that the CACS patient population is quite large; the condition affects up to 80% of patients with advanced cancer. For the corporate segment, the interest from multiple pharmaceutical companies in ART27.13 suggests a strong validation of the data package Artelo Biosciences, Inc. has generated so far.

Also, consider the intellectual property protection for ART27.13, as this directly impacts the value proposition to potential partners: the European Patent Office issued a Notice of Allowance for the intended commercial formulation through 2041. That's a long runway for a potential partner to plan around.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Cost Structure

You're looking at the core expenditures Artelo Biosciences, Inc. (ARTL) faces to keep its clinical pipeline moving forward as of late 2025. These costs are typical for a clinical-stage biopharma company heavily reliant on external funding.

Cost Component	Q3 2025 Amount (USD)	Comparison Context
Research and Development (R&D) Expenses	$1.3 million	Up from $0.3 million in Q3 2024
General and Administrative (G&A) Expenses	$1.8 million	Up from $0.9 million in Q3 2024
Gross Proceeds from Capital Raising (Q3 2025)	$3.4 million total	$0.4 million from ATM + $3.0 million from Public Offering

The cost structure is dominated by the clinical and operational spend required to advance its therapeutic candidates.

• Heavy Research and Development (R&D) expenses, which were $1.3 million in Q3 2025.
• General and Administrative (G&A) costs, totaling $1.8 million in Q3 2025.
• Costs associated with intellectual property protection and maintenance, which are factored into the overall operating expenses, including the potential cost of defending intellectual property disputes.
• Capital raising costs, including professional fees associated with efforts that generated gross proceeds of $3.4 million in Q3 2025 through an At-The-Market Offering Agreement and a confidentially marketed public offering.

The increase in operating expenses for the quarter ended September 30, 2025, was primarily the result of increases in professional fees associated with capital raising efforts and increases in research and development expenditures related to clinical programs. Finance: draft 13-week cash view by Friday.

Artelo Biosciences, Inc. (ARTL) - Canvas Business Model: Revenue Streams

You're looking at the revenue side for Artelo Biosciences, Inc. (ARTL) as of late 2025, and honestly, it's what you expect from a company deep in clinical development. The model is almost entirely reliant on external capital right now, not product sales.

Currently $0.000 in product revenue, typical for a clinical-stage biotech. That zero reflects the focus on advancing the pipeline through trials rather than commercialization.

The primary, immediate revenue driver is capital markets activity. You saw proceeds from equity financing, such as the $3.0 million public offering completed in September 2025. That offering consisted of common stock and pre-funded warrants.

Here's a quick look at the capital raised through financing activities reported around the Q3 2025 period to fund the R&D expenses, which were $1.3 million for the quarter:

Financing Source	Q3 2025 Gross Proceeds	First Nine Months 2025 Gross Proceeds
Public Offering (September 2025)	$3.0 million	$3.0 million
At-The-Market (ATM) Offering	$0.4 million	Not specified separately for YTD
Total Equity Issuance (YTD)	Not specified separately for Q3	$4.39 million
Convertible Notes (YTD)	Not specified	$0.74 million
Warrant Exercises (YTD)	Not specified	$0.13 million

Future milestones and royalty payments from out-licensing agreements represent the potential, non-dilutive revenue stream. While Artelo Biosciences is actively seeking partners, specific dollar amounts tied to future milestones or royalties aren't locked in yet, but that's definitely the goal for long-term sustainability.

Also critical to the cash runway was the capital raised via the At-The-Market (ATM) offering, which generated $0.4 million in gross proceeds during Q3 2025. This ATM program allows the company to sell shares opportunistically.

To be fair, the financing picture for the first nine months of 2025 shows a broader reliance on capital markets to bridge the gap:

• Total equity raised through various issuances in the first nine months of 2025 was $4.39 million.
• Capital secured via convertible notes totaled $0.74 million for the same nine-month period.
• An additional $0.13 million came from warrant exercises year-to-date.